Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (Nasdaq: PGNY) reported record Q1 2026 revenue of $328.5M, gross profit of $83.1M and net income of $24.2M ($0.29 diluted). Adjusted EBITDA was $56.6M. The company repurchased 8.8M shares to date and had 595 clients and ~7.185M average members.
Progyny (NASDAQ: PGNY) will report results for the quarter ended March 31, 2026, after market close on Thursday, May 7, 2026. A conference call will follow at 4:45 p.m. ET (1:45 p.m. PT). A press release will be issued before the call and a live webcast and archived replay will be available on the investor website.
Progyny (Nasdaq: PGNY) launched Progyny Select, the industry’s first fully insured supplemental fertility and women’s health plan for small U.S. employers, announced April 16, 2026. Key features include fixed PEPM pricing, comprehensive coverage (IVF, IUI, genetic testing), concierge care advocates, and support across pregnancy, postpartum, and menopause.
The plan will be distributed via brokers, health plan partners, and agents for implementation in 2027 plan years.
Progyny (NASDAQ:PGNY) marks its 10-year anniversary on April 1, 2026, celebrating growth in women’s health and family building benefits.
The company highlights support for over 470,000 members, more than 600 employers, coverage of 7.2 million lives, and data-driven clinical outcomes improving IVF and menopause access.
Progyny (Nasdaq: PGNY) announced that company executives will participate in investor conferences in March 2026, including Leerink Partners, Barclays Global Healthcare, and KeyBanc Capital Markets.
Specific sessions: CFO Mark Livingston (fireside chat) on March 10 at 10:40 a.m. ET; CEO Pete Anevski (fireside chats) on March 11 at 1:00 p.m. ET and March 17 at 3:00 p.m. ET; COO Melissa Cummings (panel) on March 17 at 12:00 p.m. ET. Live audiocasts and replays will be available in the Events and Presentations section of Progyny's investor relations website.
Progyny (Nasdaq: PGNY) reported 4Q2025 revenue $318.4M (+6.7% YoY) and FY2025 revenue $1.2887B (+10% YoY). Gross profit was $76.9M in 4Q and $304.5M for FY. Net income was $12.5M (4Q) and $58.5M (FY). Adjusted EBITDA was $51.4M (4Q) and $222.1M (FY).
The company generated $210.2M operating cash flow in 2025, repurchased ~6.5M shares (~$160M), ended year with no debt and ~555 clients.
Progyny (Nasdaq: PGNY) will report fourth quarter and full year 2025 results after market close on February 26, 2026.
The company will host a conference call at 4:45 p.m. ET and publish a press release before the call. Dial‑in numbers, passcode 265484, replay through March 5, 2026, and a live webcast/archive are available on the investor website.
Progyny (Nasdaq: PGNY) expects its fourth quarter and full year results for the period ending December 31, 2025 to be slightly above the financial guidance ranges it provided in November, driven by stronger-than-expected member engagement late in the quarter. The company noted this outlook excludes any non-cash net income impacts tied to the previously announced departure of Michael Sturmer as president. Progyny will discuss these updated expectations at the JP Morgan Healthcare Conference presentation on Jan 13, 2026 at 10:30 a.m. ET, with a live audiocast and replay available on its investor website.
Progyny (Nasdaq: PGNY) published U.S. men’s health research on Nov 20, 2025 exploring attitudes, barriers, and actions around fertility.
Key findings: 75% see fertility as a shared issue, 82% are comfortable discussing fertility with partners, but only 46% of men with fertility issues sought support. Top barriers: fear of diagnosis (64%), cost (56%), and embarrassment (48%). 56% made lifestyle changes after recognizing links between fertility and overall health. Progyny highlights employer opportunity to expand fertility benefits and offers men’s resources including urology networks, testing, and education.
Progyny (Nasdaq: PGNY) announced that CFO Mark Livingston will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.
A live audiocast and replay will be available from the Events and Presentations section of Progyny’s investor website at http://investors.progyny.com.